| Teng, Gao-Jun |
NCT05073744: Nalbuphine Versus Morphine for Perioperative Tumor Ablation |
|
|
| Recruiting | 4 | 316 | RoW | Nalbuphine, Tumor ablation using nalbuphine, Morphine, Tumor ablation using morphine | Zhongda Hospital | Nalbuphine Allergy, Ablation, Safety | 08/23 | 08/23 | | |
NCT05912686: High-Dose Atorvastatin for Vascular Wall Protection in Thrombectomy Patients |
|
|
| Not yet recruiting | 4 | 162 | RoW | Atorvastatin 80mg, Atorvastatin 20mg | Zhongda Hospital | Mechanical Thrombectomy, Acute Ischemic Stroke | 12/25 | 07/26 | | |
NCT05472896: TACE With Dicycloplatin(TP21) in Unresectable HCC |
|
|
| Recruiting | 3 | 332 | RoW | cTACE, Dicycloplatin (TP21), Epirubicin | Gao-jun Teng | Hepatocellular Carcinoma | 06/24 | 06/24 | | |
NCT05344924: TACE Combined With Penpulimab and Anlotinib for Advanced HCC |
|
|
| Recruiting | 2/3 | 109 | RoW | TACE+penpulimab+anlotinib vs. penpulimab+anlotinib, The combination of penpulimab+anlotinib with or without TACE | Zhongda Hospital | Hepatocellular Carcinoma | 03/23 | 03/24 | | |
NCT05280444: Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 216 | RoW | Idarubicin Hydrochloride for Injection, Anbijian | Zhongda Hospital | Hepatocellular Carcinoma | 06/23 | 07/23 | | |
| Recruiting | 2 | 72 | RoW | Tislelizumab in combination with cTACE, BGB-A317 | Zhongda Hospital | Hepatocellular Carcinoma | 11/22 | 11/23 | | |
| Recruiting | 2 | 32 | RoW | HAIC combined with donafenib and sintilimab, HAIC-donafenib-sintilimab | Zhongda Hospital | Cholangiocarcinoma | 06/23 | 07/23 | | |
| Recruiting | 1/2 | 60 | RoW | Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres | Zhongda Hospital | Unresectable Colorectal Liver Metastases | 12/24 | 12/24 | | |
NCT05957640: Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | Yttrium-90 carbon microspheres SIRT | Zhongda Hospital | Unresectable Hepatocellular Carcinoma | 05/25 | 05/25 | | |
| Completed | N/A | 826 | RoW | TACE+ICIs, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 05/22 | 02/23 | | |
NCT04060797: Endovascular Denervation Improves Limb Ischemia in Patients With Peripheral Artery Disease |
|
|
| Completed | N/A | 38 | RoW | endovascular denervation, PTA | Zhongda Hospital | PAD | 09/21 | 09/21 | | |
| Recruiting | N/A | 30 | RoW | Endovascular Denervation | Zhongda Hospital | Type 2 Diabetes Mellitus | 09/22 | 12/22 | | |
NCT05703750: Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301) |
|
|
| Recruiting | N/A | 228 | RoW | TACE ± Systemic therapy | Zhongda Hospital | Hepatocellular Carcinoma, Portal Hypertension | 06/23 | 12/23 | | |
NCT05704192: CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302) |
|
|
| Recruiting | N/A | 373 | RoW | TACE ± Systemic therapy | Zhongda Hospital | Hepatocellular Carcinoma, Portal Hypertension | 06/23 | 12/23 | | |
| Recruiting | N/A | 474 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
NCT05631561: Endovascular Denervation for the Treatment of Type 2 Diabetes Mellitus |
|
|
| Active, not recruiting | N/A | 30 | RoW | Endovascular denervation System (Generator and Catheter ) | Shanghai Golden Leaf MedTec Co. Ltd | Type 2 Diabetes Mellitus (T2DM) | 04/24 | 02/25 | | |
CHANCE2202, NCT05332496: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC |
|
|
| Recruiting | N/A | 220 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 09/23 | | |
| Active, not recruiting | N/A | 188 | RoW | Camrelizumab, TACE, Apatinib | Zhongda Hospital | Hepatocellular Carcinoma | 08/24 | 01/26 | | |
NCT06195917: Robotic-assisted Percutaneous Transhepatic Puncture |
|
|
| Recruiting | N/A | 20 | RoW | Robotic-assisted Interventional Percutaneous transhepatic puncture | Zhongda Hospital | Liver Diseases | 04/24 | 05/24 | | |
CHANCE023, NCT06024252: Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study |
|
|
| Not yet recruiting | N/A | 200 | NA | TACE, Atezolizumab, Bevacizumab | Zhongda Hospital | HCC | 12/23 | 06/24 | | |
NCT06190665: DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC |
|
|
| Recruiting | N/A | 188 | RoW | DEB-TACE with visualable microspheres, DEB-TACE with PVA microspheres | Zhongda Hospital | Hepatocellular Carcinoma | 12/25 | 12/26 | | |
ST-Y90-CP01, NCT06447727: Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM |
|
|
| Recruiting | N/A | 30 | RoW | SIRT with Yttrium-90 Microspheres, FOLFIRI and Bevacizumab | Zhongda Hospital | Colorectal Cancer Metastatic | 11/25 | 11/25 | | |
NCT06607120: Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies |
|
|
| Recruiting | N/A | 950 | RoW | | Zhongda Hospital | Hepatocellular Carcinoma | 01/25 | 03/25 | | |
NCT06593964: TACE With Thermosensitive Nanogel Versus Embosphere for HCC |
|
|
| Recruiting | N/A | 188 | RoW | Thermosensitive Nanogel Embolic Agent | Zhongda Hospital | Unresectable Hepatocellular Carcinoma | 04/26 | 04/26 | | |
NCT05956860: Radial Access for Abdominopelvic Vascular Intervention |
|
|
| Recruiting | N/A | 1143 | RoW | abdominopelvic vascular intervention through the radial artery access | Zhongda Hospital, Terumo Medical Corporation | Vascular Access Device Complications | 12/24 | 12/25 | | |
EDPAD, NCT05345431: Endovascular Denervation for the Treatment of Patients With Peripheral Arterial Disease |
|
|
| Recruiting | N/A | 54 | RoW | endovascular denervation, PTA | Zhongda Hospital | PAD | 06/25 | 06/26 | | |
NCT06021015: Safety and Efficacy of Polyvinyl Alcohol Sodium Acrylate Embolization Microspheres for CRLM |
|
|
| Not yet recruiting | N/A | 72 | NA | Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）, Irinotecan and HepaSphere Microspheres | Zhongda Hospital | Colorectal Cancer Liver Metastasis | 06/25 | 12/25 | | |
CHANCEsub, NCT05278195: Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers |
|
|
| Recruiting | N/A | 300 | RoW | | Zhongda Hospital | Hepatocellular Carcinoma | 12/22 | 12/23 | | |
| Lu, Jian |
NCT06195917: Robotic-assisted Percutaneous Transhepatic Puncture |
|
|
| Recruiting | N/A | 20 | RoW | Robotic-assisted Interventional Percutaneous transhepatic puncture | Zhongda Hospital | Liver Diseases | 04/24 | 05/24 | | |
